LEADER 00865cam0-2200313---450- 001 990004843640403321 005 20140721144328.0 035 $a000484364 035 $aFED01000484364 035 $a(Aleph)000484364FED01 035 $a000484364 100 $a19990604d1972----km-y0itay50------ba 101 0 $aspa 102 $aES 105 $a--------001ay 200 1 $aDuelo en el paraiso$fJuan Goytisolo$gedición definitiva establecida por el autor 205 $a5. ed. 210 $aBarcelona$cDestino$d1972 215 $a282 p.$d19 cm 225 1 $aAncora y Delfin$v183 676 $a863.6 700 1$aGoytisolo,$bJuan$f<1931- >$0131792 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990004843640403321 952 $a863.6 GOY 6$bIst.f.m.19583$fFLFBC 959 $aFLFBC 996 $aDuelo en el paraíso$9202323 997 $aUNINA LEADER 01797nam 2200337 450 001 9910714444903321 005 20230614222012.0 035 $a(CKB)3790000000049559 035 $a(NjHacI)993790000000049559 035 $a(EXLCZ)993790000000049559 100 $a20230614d2014 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aFollow-On Biologics $ethe law and intellectual property issues /$fJohn R. Thomas 210 1$aWashington, District of Columbia :$cCongressional Research Service,$d2014. 215 $a1 online resource (21 pages) 225 0 $aCRS report for Congress 330 $aReviews intellectual property and innovations issues within context of the Biologics Price Competition and Innovation Act (BPCIA) of 2009, which established expedited licensor pathway for competing versions of previously marketed biologics, created FDA-administered periods of data protection and marketing exclusivity for certain brand-name drugs and follow-on products, and provided a patent dispute resolution procedure for use by brand-name and follow-on biologic manufacturers. Provides introduction to biologics industry, which includes biotechnology and biopharmaceutical industries; reviews regulatory and intellectual property provisions of BPCIA; and considers potential market for biosimilars and possible responses that may arise in wake of this legislation. 606 $aBiotechnology$xLaw and legislation 615 0$aBiotechnology$xLaw and legislation. 676 $a346.0486 700 $aThomas$b John R.$01362636 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910714444903321 996 $aFollow-On Biologics$93382092 997 $aUNINA